PhaseV, a developer of advanced AI/ML solutions to optimise clinical development, said on Thursday that it has received three 2025 industry honours.

The company was named to CB Insights' Digital Health 50 list of the most promising private companies in digital health for the category of Drug Discovery and Development. It was also included on the TechCrunch AI Disruptors 60 list, and its platform was selected as the BioTech Breakthrough 'Analytics Solution of the Year'.

According to PhaseV, its AI-driven platform delivers value to clinical sponsors by accelerating drug pipelines, reducing trial costs by up to 50% and speeding up execution by up to 40%. It improves trial probability of success by over 30%, directly unlocking billions of dollars in otherwise missed asset value. The platform is built on a proprietary data lake integrated with over two million patient-level records, supporting more than 20 predictive disease models across a wide range of therapeutic areas.